Highlights

• Novel biochemical approach to the diagnosis of anxiety  associated disorders
• Objective, accurate test for post traumatic stress disorder (PTSD) and other Anxiety disorders
• Quantified acetylcholine regulation parameters for assessing treatment efficacy
• Kit consists of a multi-well plate and reagents.
• Cholinergic status of patient read by a standard ELISA reader and calculated by an available set of equations

Our Innovation
Blood test for biochemical parameters reflecting the specific  cholinergic  related enzymatic activity in the circulation was substantiated by comparison with population baseline database of Anxiety diagnosis questionnaire results. The blood test enables reliable prediction of trait and state anxiety measures.

Key Features

• Provides early and objective diagnosis of  anxiety  and PTSD risk without need to  rely  on  patient subjective reports.
• Provides objective evaluation of the efficacy of Anxiety treatment
• Can be used  for specific neurological patient groups with defined anxiety-associated  symptoms, such as hypersensitivity, depression or cognitive deterioration, for predicting future recovery prospects under various treatment paradigms

Development Milestones

• Broadening scope for detection of treatment efficacy
• Seeking strategic partner for development and commercialization

The Opportunity

In the United States, roughly 3.6 days of work impairment per month associated with PTSD translates into an annual productivity loss in excess of $3 billion

Granted US 7,494,783; Israel 174904